Randomized Controlled Trials for Neuromyelitis Optica Spectrum Disorder: A Review of Trial Architecture

Conclusions: Ethical considerations for the use of placebo should change in light of the approval of 3 therapies for seropositive NMOSD. Remaining challenges for clinical trials in NMOSD include the assessment of long-term safety and efficacy, standardization of trial design and endpoints, and head-to-head study designs.
Source: The Neurologist - Category: Neurology Tags: Review Article Source Type: research